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INTRODUCTION
Breast cancer is the second most prevalent cancer among 
newly developed cancers in Korean women and the 5-year 
survival rates of breast cancer have notably improved in recent 
years [1]. Human epidermal growth factor receptor 2 (HER2) and 
topoisomerase II alpha (TOP2A) have been known as predic-
tive markers for benefit of anthracyclines [2-7]. However, for 
the issue of an increased copy number of the chromosome 17 
centromere (CEP17) (called CEP17 multiplication in this 
study), its significance in breast cancer outcome and response 
to specific chemotherapy regimens is still uncertain, especially 
in patients with non-amplified HER2 or normal TOP2A status.
The TOP2A gene is located on chromosome 17q21 and the 
TOP2A protein is a key enzyme for DNA replication, cell cycle 
progression and chromosome segregation and it is a molecular 
target for anthracyclines [8]. TOP2A is near HER2 on chromo-
some 17; therefore co-amplification of both genes is not uncom-
mon [9]. About 40-90% of TOP2A-amplified tumors showed 
amplification of HER2 as well, and one third of HER2-positive 
tumors were TOP2A-amplified [8,10]. Studies have reported 
that TOP2A amplification or alteration (either amplification or 
deletion) was associated with a favorable response to anthra-
cycline-containing therapy [2,5,11]. However, in a recent study, 
CEP17 multiplication was shown to be a predictor of anthra-
cycline benefit whereas there was no significant correlation 
between HER2 or TOP2A status and anthracycline benefit [12]. 
Polysomy indicates that the number of a particular chro-
mosome is greater than diploid and it has been represented by 
≥3 signals in fluorescent in situ hybridization (FISH) assays 
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Purpose: This study aimed to investigate the clinical significance 
of chromosome 17 centromere (CEP17) multiplication (increased 
copy number of CEP17) related to human epidermal growth     
factor receptor 2 (HER2) and topoisomerase II alpha (TOP2A) 
status in patients with invasive breast cancer. Methods: We     
constructed tissue microarrays using 594 invasive breast cancer 
samples and performed single-color silver-enhanced in situ           
hybridization (SISH) assay for HER2, TOP2A, and CEP17 to         
assess for copy number aberrations. The association of CEP17 
multiplication with patient survival was analyzed according to 
HER2 and TOP2A status. Results: Among 567 informative cases, 
HER2 amplification was noted in 22.8%, TOP2A amplification in 
8.3% and TOP2A deletion in 11.1%. CEP17 multiplication was 
identified in 33.2% and was significantly associated with worse 
overall survival (OS) (p=0.02) and disease-free survival (DFS) 
(p=0.02). CEP17 multiplication correlated with patient survival in 
patients with normal TOP2A or non-amplified HER2 status, but 
the prognostic significance was lost in those with altered TOP2A 
or amplified HER2. On multivariate analyses, CEP17 multiplica-
tion was an independent prognostic factor for poorer OS (p=0.02) 
and DFS (p=0.01) in patients with normal TOP2A and non-am-
plified HER2. Conclusion: CEP17 multiplication was identified as 
a promising prognostic marker in patients with invasive breast 
cancer exhibiting either non-amplified HER2 or normal TOP2A 
status.
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with a probe targeted to the centromeric area of the particular 
chromosome [13]. Recent studies reported that chromosome 
17 polysomic cases defined by multiplication of CEP17 in FISH 
assays were frequently related to 17q gain involving centromeres 
or amplification of the centromeric region rather than whole 
chromosome multiplication (true chromosome 17 polysomy) 
[13,14]. Therefore, CEP17 multiplication by in situ hybridiza-
tion does not indicate true chromosomal 17 polysomy in all 
cases. As HER2 gene amplification and TOP2A alteration are 
determined by the HER2 to CEP17 ratio and the TOP2A to 
CEP17 ratio by FISH or the silver-enhanced in situ hybridiza-
tion (SISH) method, increased number of CEP17signals due 
to gain or amplification of the centromeric regions of chromo-
some 17 (not true polysomy) may provide misleading HER2 
or TOP2A gene status assessment results [13,15]. This consid-
eration may explain at least in part the conflicting reports about 
the clinical implications of TOP2A alteration or HER2 ampli-
fication [15]. CEP17 multiplication in the absence of HER2 
amplification or TOP2A alteration is not a rare event, but few 
studies on its clinical significance related to HER2 or TOP2A 
status have been completed [16].
This study aimed to investigate the clinical significance of 
CEP17 multiplication related to TOP2A alteration and HER2 
amplification in patients with invasive breast cancers by corre-
lating CEP17 multiplication with prognostic and predictive 
pathologic parameters and patient survival.
METHODS
Case selection and construction of tissue microarray blocks
For this study, we collected 594 primary invasive breast cancer 
cases which were treated surgically at Yeungnam University 
Hospital, Daegu, South Korea between January 1995 and     
January 2004. We reviewed the slides of all cases and selected 
a representative tumor block per case for the construction of 
tissue microarrays (TMAs). A pair of 2-mm-diameter tissue 
cores were retrieved from each tumor block and transferred 
to the recipient block (Accumax
TM array; ISU Abxis, Seoul, 
Korea). Thirteen TMA blocks were created from 594 tumor 
blocks. The patient age at initial diagnosis, tumor size, histo-
logical tumor grade [17], lymph node status, surgery type,   
adjuvant chemotherapy regimens and follow-up data were 
obtained from the pathology reports and patients’ medical   
records. This study was approved by the Institutional Review 
Board of Yeungnam University Hospital (PCR-10-132).
Immunohistochemistry
Four-micrometer-thick TMA sections were immunostained 
for estrogen receptor (ER) (SP1, CONFIRM
TM, rabbit mono-
clonal; Ventana Medical Systems, Tucson, USA) and proges-
terone receptor (PR) (1E2, CONFIRM
TM, rabbit monoclonal; 
Ventana Medical Systems) with UltraView
TM universal DAB 
detection kit (Ventana Medical Systems). Immunohistochem-
istry (IHC) was performed on the automated Benchmark
® 
platform (Ventana Medical Systems) according to the manu-
facturer’s recommendations. The staining results for ER and 
PR were considered positive if there was ≥1% positive tumor 
nuclei within the tumor according to the American Society of 
Clinical Oncology/College of American Pathologists (ASCO/
CAP) guideline [18]. 
Single-color SISH analysis
Three tissue sections of 4 μm-thickness per case were           
prepared for the SISH analysis. SISH was performed using 
INFORM
® TOP2A DNA, INFORM
® HER2 DNA and Chro-
mosome 17 (CEP17) Probes (Ventana Medical Systems) using 
the Ventana Benchmark
® series of automated slide stainer. 
Probes for HER2, TOP2A, and CEP17 were labeled with dini-
trophenol (DNP). The HER2 DNA probe was denatured at 
95°C for 12 minutes and hybridization was performed at 52°C 
for 2 hours. After hybridization, an appropriate stringency 
wash (three times at 72°C) was performed. The TOP2A DNA 
probe was denatured at 80°C for 12 minutes and hybridization 
was performed at 44°C for 2 hours. After hybridization, an 
appropriate stringency wash (one time at 72°C) was performed. 
The CEP17 probe was denatured at 95°C for 12 minutes and 
hybridization was performed at 44°C for 2 hours. After hybrid-
ization, appropriate stringency washes were performed three 
times at 59°C. The HER2, TOP2A, and CEP17 DNP-labeled 
probes were visualized by using the rabbit anti-DNP primary 
antibody and the UltraView
TM SISH Detection Kit, which con-
tained a goat anti-rabbit antibody conjugated to horseradish 
peroxidase utilized as the chromogenic enzyme. Silver precip-
itation was deposited in the nuclei following the sequential 
addition of silver acetate, hydroquinone, and H2O2. The slides 
were then counterstained with Ventana hematoxylin II for     
interpretation by light microscopy.
The hybridization signals for HER2, TOP2A and CEP17 were 
counted in more than 20 non-overlapping nuclei per case. Nor-
mal HER2, TOP2A or CEP17 signals of endothelial cells, stro-
mal fibroblasts, and lymphocytes served as the internal positive 
control. A discrete dot was counted as a single copy of HER2, 
TOP2A or CEP17. The size of these single dots was used as a 
reference to determine the relative number of amplified copies 
in cancer cell nuclei. A small cluster of multiple signals was 
counted as six signals and a large cluster was counted as 12 sig-
nals according to the manufacturer’s instructions. The HER2/
CEP17 and TOP2A/CEP17 ratios were calculated in each case. 26   Aeri Kim, et al.
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HER2 amplification was defined when the HER2/CEP17 ratio 
was >2.2, equivocal to HER2 amplification was defined when 
the HER2/CEP17 ratio was 1.8-2.2 and negative for HER2 
amplification was defined when the HER2/CEP17 ratio was 
<1.8 [19]. We categorized equivocal cases as HER2-amplified 
cases when the average HER2 signal per nucleus is >6 and 
equivocal cases with ≤6 HER2 signal per nucleus were catego-
rized as negative for HER2 amplification for this study. TOP2A 
amplification was defined when the TOP2A/CEP17 ratio was 
≥2.0 and TOP2A deletion was defined when the TOP2A/
CEP17 ratio was  ≤0.8. If the ratio of TOP2A/CEP17 was         
between 0.8 and 2.0, we considered the case as having normal 
TOP2A [5]. We defined CEP17 multiplication when the cases 
show increased copy number for CEP17 (>2 signals/nucleus) 
in SISH assay [6].
Statistical analysis
Statistical analysis was performed using SPSS version 18.0 
for Windows (SPSS Inc., Chicago, USA). Chi-square test and 
Fisher’s exact test were used to determine correlations between 
CEP17 multiplication and clinicopathological parameters. 
Overall survival (OS) and disease-free survival (DFS) for the 
groups defined by TOP2A or HER2 status and CEP17 multi-
plication were plotted using Kaplan-Meier survival curves   
analyzed by the log-rank test. We obtained the hazard ratios 
and associated 95% confidence intervals using the Cox uni-
variate model to compare groups defined by clinicopathologi-
cal parameters. Multivariate analysis was carried out using 
Cox’s regression. A p-value of <0.05 was considered statisti-
cally significant.
RESULTS
Patient characteristics 
Of 594 invasive breast cancer samples, we obtained immu-
nohistochemical and SISH results from 567 cases due to non-
informative cores by acquisition tissue cores from non-neo-
plastic areas or loss of cores while performing immunohisto-
chemical or SISH analysis. Among 567 patients, 174 underwent 
breast conserving surgery and 393 underwent mastectomy. 
Patient ages ranged from 20 to 85 years (mean, 47.1 years). 
The histological types included invasive ductal carcinoma, not 
otherwise specified (513 cases, 90.5%); invasive lobular carci-
noma (20 cases, 3.5%); invasive micropapillary carcinoma (14 
cases, 2.5%); mucinous carcinoma (9 cases, 1.6%); medullary 
carcinoma (4 cases, 0.7%); invasive tubular carcinoma (4 cases, 
0.7%); invasive papillary carcinoma (2 cases, 0.4%); and inva-
sive cribriform carcinoma (1 case, 0.2%). Tumor sizes varied 
from 0.5 to 11 cm (mean, 2.5 cm).
Among 567 patients, 263 (46.4%) were pT1, 280 (49.4%) 
were pT2 and 24 (4.2%) were pT3. At the time of surgery, 279 
(49.2%) patients had positive lymph nodes. The histological 
grade was available in 526 cases; 92 (16.2%) were grade 1, 146 
(25.7%) were grade 2, and 288 (50.8%) were grade 3. For         
adjuvant chemotherapy, 346 patients (61%) received anthra-
cycline-based chemotherapy including combined 5-fluoro-
uracil (5-FU), epirubicin and cyclophosphamide (CEF); com-
bined 5-FU, doxorubicin and cyclophosphamide; combined 
doxorubicin and cyclophosphamide; or combined epirubicin 
and taxol. Another 142 patients (25%) received chemothera-
peutic regimens including combined cyclophosphamide, 
methotrexate and 5-FU (CMF); taxol alone; oral 5-FU alone; 
or oral furtulon alone. The remaining 79 patients had no     
chemotherapy. The mean follow-up period was 87.4 months 
(range, 7-170 months). Patient characteristics are summarized 
in Table 1.
Table 1. Characteristics of cases
Characteristics     No. (%)
Age (yr)*                                              47.1 (20-85)
Type of surgery
   Breast conserving surgery 174 (30.7)
   Mastectomy 393 (69.3)
Histologic type
   Ductal 513 (90.5)
   Lobular 20 (3.5)
   Micropapillary 14 (2.5)
   Mucinous 9 (1.6)
   Medullary 4 (0.7)
   Tubular 4 (0.7)
   Papillary 2 (0.4)
   Cribriform 1 (0.2)
Tumor size
   pT1 263 (46.4)
   pT2 280 (49.4)
   pT3  24 (4.2)
Lymph node metastasis
   Absent 284 (50.1)
   Present 279 (49.2)
   Unknown 4 (0.7)
Histological grade
   1 92 (16.2)
   2 146 (25.7)
   3 288 (50.8)
   Unknown 41 (7.2)
Chemotherapy
   Anthracycline 346 (61)
   Non-anthracycline 142 (25)
   Not done 79 (13.9)
Died of disease 72 (12.7)
Recurrence/Metastasis 90 (15.9)
Total 567 (100)
*Mean (range).CEP17 Duplication in Breast Cancer 27
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IHC and SISH results 
We interpreted the staining results in both cores to obtain a 
representative result for each parameter. Among 567 informa-
tive cases, ER was positive in 380 (67%) and PR was positive 
in 328 (57.8%) cases. A total of 129 (22.8%) cases had HER2 
gene amplification (Figure 1). For the TOP2A gene, 457 (80.6%) 
had normal TOP2A, 47 (8.3%) had TOP2A amplification and 
63 (11.1%) had TOP2A deletion (Figure 2). Multiplication of 
CEP17 was identified in 188 (33.2%) cases (Figure 3). 
Association between HER2 and TOP2A status
TOP2A alteration was more frequent in patients with ampli-
fied HER2 than in those with non-amplified HER2. Of 129 
HER2-amplified tumors, TOP2A deletion and amplification 
were observed in 34 (26.4%) and 31 (24%), respectively. In 
contrast, of 438 cases with non-amplified HER2, TOP2A           
deletion and amplification were observed in 29 (6.6%) and 16 
(3.7%), respectively (Table 2). 
Association of CEP17 multiplication with tumor characteristics 
and HER2 or TOP2A status
Multiplication of CEP17 was associated with high histologi-
cal grade (p<0.01), HER2 amplification (p<0.01), and TOP2A 
alteration (p<0.01). HER2-amplified tumors were twice as like-
Figure 1. Silver-enhanced in situ hybridization results for HER2. (A) Negative for HER2 amplification. The average number of HER2 signals per nucleus 
was 1.9 and the HER2/CEP17 ratio was 0.95 (×400). (B) Positive for HER2 amplification. The average number of HER2 signals per nucleus was 20 
and the HER2/CEP17 ratio was 9.62 (×400). 
A 20 μm B 20 μm
Figure 2. Silver-enhanced in situ hybridization results for TOP2A. (A) Deletion of TOP2A. The majority of tumor cells have single signal for TOP2A 
(×400). The average number of TOP2A signals per nucleus was 1.2 and the TOP2A/CEP17 ratio was 0.7. (B) Amplification of the TOP2A gene. 
Hybridization signals are conglomerated (×400). The average number of TOP2A signals per nucleus was 20 and the TOP2A/CEP17 ratio was 17.4. 
A 20 μm B 20 μm28   Aeri Kim, et al.
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ly to have CEP17 multiplication as were those without HER2 
amplification (55.8% [72/129] vs. 26.5% [116/438]). TOP2A-
amplified and -deleted tumors were also significantly more 
likely to have CEP17 multiplication than were those that show 
normal TOP2A status (40.4% [19/47] and 84.1% [53/63] vs. 
25.4% [116/457], respectively) (Table 3).
Association of TOP2A or HER2 status and CEP17 multiplication 
with patient survival 
When TOP2A status was compared with patient survival, 
there was no statistically significant difference of OS and DFS 
between the TOP2A-amplified, TOP2A-deleted and TOP2A-
normal groups. The patients with amplified HER2 showed 
poorer DFS than those with non-amplified HER2, but the dif-
ference was not statistically significant for OS. Multiplication 
of CEP17 was associated with a poor prognosis in all patients, 
but the survival difference was lost in subgroups by the che-
motherapy regimen (Table 4). 
In patients with non-amplified HER2, CEP17 multiplication 
was associated with worse OS (p=0.01) and DFS (p=0.01). 
However, CEP17 multiplication did not correlate with survival 
in patients with amplified HER2. In patients with normal       
TOP2A status, CEP17 multiplication was significantly associ-
Figure 3. Silver-enhanced in situ hybridization results for CEP17. (A) Normal CEP17 signals. The majority of cells have one or two hybridization       
signals (×400). The average number of CEP17 signals per nucleus was 1.65. (B) CEP17 multiplication. The average number of CEP17 signals per 
nucleus was 3.4 in this case (×400). 
A 20 μm B 20 μm
Table 2. Correlation between HER2 status and TOP2A status
TOP2A status
HER2 amplification
p-value
Negative Positive
Normal 393 (86) 64 (49.6) <0.01
Deletion 29 (6.6) 34 (26.4)
Amplification 16 (3.7) 31 (24)
Total 438 (100) 129 (100)
HER2=human epidermal growth factor receptor 2; TOP2A=topoisomerase II 
alpha. 
Table 3. Association of CEP17 multiplication with clinicopathological 
features
Characteristics
CEP17 multiplication
p-value Present, No. (%) 
(n=188) 
Absent, No. (%) 
(n=379)
Age (yr) 0.62
   <50  127 (67.6) 248 (65.4)
   ≥50  61 (32.4) 131 (34.6)
Tumor size (cm) 0.89
   ≤2  88 (46.8) 175 (46.2)
   >2 100 (53.2) 204 (53.8)
Histological grade <0.01
   1 & 2  53 (29.4) 185 (53.5)
   3 127 (70.6) 161 (46.5)
Lymph node metastasis 0.26
   Absent  88 (47.1) 196 (52.1)
   Present   99 (52.9) 180 (47.9)
Estrogen receptor 0.85
   Positive 125 (66.5) 255 (67.3)
   Negative  63 (33.5) 124 (32.7)
Progesterone receptor 0.39
   Positive 104 (55.3) 224 (59.1)
   Negative   84 (44.7) 155 (40.9)
HER2 <0.01
   Positive  72 (38.3)  57 (15)
   Negative 116 (61.7) 322 (85)
TOP2A <0.01
   Normal 116 (61.7) 341 (90)
   Deletion  53 (28.2)  10 (2.6)
   Amplification  19 (10.1)  28 (7.4)
CEP17=chromosome 17 centromere; HER2=human epidermal growth fac-
tor receptor 2; TOP2A= topoisomerase II alpha. CEP17 Duplication in Breast Cancer 29
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ated with worse OS (p=0.02) and DFS (p=0.02), but it was 
not associated with either OS or DFS in patients with TOP2A 
alteration (Figure 4).
In patients with both non-amplified HER2 and normal     
TOP2A status (n=393), tumor size, lymph node status, histo-
logical grade and CEP17 multiplication correlated with OS 
and DFS in univariate analyses (Table 5). The prognostic sig-
nificance of CEP17 multiplication was also observed in patients 
treated with anthracyclines (n=221) (OS, p=0.03; DFS, p=
0.01). The survival differences in both OS and DFS according 
to CEP17 multiplication were apparent, but not statistically 
significant in patients treated with non-anthracyclines (n=104) 
(OS, p=0.30; DFS, p=0.10). In multivariate analyses, CEP17 
multiplication was an independent prognostic factor for poor 
OS (p=0.02) and DFS (p=0.01) together with large tumor 
size and lymph node metastasis in patients with both normal 
TOP2A and non-amplified HER2 status regardless of treatment 
type (Table 6).
DISCUSSION
HER2 gene amplification or HER2 protein overexpression 
has been considered predictive of a favorable response to         
anthracycline chemotherapy [20-22]. However, recent studies 
indicated that such an association between HER2 and anthra-
cycline is indirect and could be mediated through TOP2A [4-
6]. TOP2A aberrations were initially reported in HER2-ampli-
fied tumors [2]. The proximity of TOP2A and HER2 genes       
in chromosome 17 has led to the conception of co-amplifica-
tion of a whole amplicon containing both genes [9]. TOP2A 
amplification and deletion have been observed with variable 
frequencies in other studies. TOP2A amplification was noted 
in 24.3-54% of HER2-positive tumors and 0-6.4% of HER2-
negative tumors, whereas TOP2A deletion was observed in 
8.1-35% of HER2-positive tumors and 0-11.7% of HER2-neg-
ative tumors [9]. 
The results of the present study corresponded well with those 
of earlier studies. TOP2A amplification was observed in 24% 
of HER2-amplified tumors and 3.7% of HER2-non-amplified 
tumors. TOP2A deletion was identified in 26.4% of HER2-
amplified tumors and 6.6% of HER2-non-amplified tumors. 
The discrepant prevalence of TOP2A alterations according to 
HER2 status can result from technical differences in measur-
ing alterations such as cutoffs used for defining amplification 
or deletion. We used the same criteria to define TOP2A altera-
tions as O’Malley et al. [5] did and evaluated TOP2A status 
using a SISH method. SISH has been introduced as an alter-
native to FISH in evaluating HER2 gene status in recent years 
and several studies have reported good concordance between 
SISH and FISH results in breast cancers [23-26]. Because SISH 
visualizes hybridization signals as light opaque silver instead 
of fluorescent spots, interpretation of SISH results can be per-
formed on a conventional light microscope. Therefore, SISH 
would be more appropriate for pathology laboratories using a 
large number of samples.
To the best of our knowledge, this is the first study to use 
the SISH method to evaluate TOP2A status. In our earlier study, 
we obtained a concordance rate of 93.7% between SISH and 
FISH for TOP2A status in 206 invasive breast cancer samples 
(unpublished data). The ASCO/CAP developed a guideline to 
improve the accuracy of HER2 testing in breast cancers [19]. As 
in the case of HER2 testing, standardization of the test method 
Table 4. Association of TOP2A, HER2, and CEP17 multiplication with patient survival
All patients (n=567) Anthracycline group (n=346) Non-anthracycline group (n=142)
OS DFS OS DFS OS DFS
HR  
(95% CI) 
p-value
HR  
(95% CI) 
p-value
HR  
(95% CI) 
p-value
HR  
(95% CI) 
p-value
HR  
(95% CI) 
p-value
HR  
(95% CI) 
p-value
TOP2A 0.94 0.77 0.98 0.86 0.36 0.22
   Normal 1 1 1 1 1 1
   Deletion 0.9 (0.4-1.9) 1.1 (0.6-2.1) 0.9 (0.4-2.2) 1.1 (0.5-2.2) 0.7 (0.9-5.3) 1.1 (0.3-5.0)
   Amplification 1.0 (0.4-2.3) 0.8 (0.4-1.8) 1.1 (0.4-2.7) 0.8 (0.3-2.0) 0 0
HER2 0.21 0.05 0.25 0.19 0.62 0.91
   Non- 
      amplification
1 1 1 1 1 1
   Amplification 1.4 (0.8-2.3) 1.6 (1.0-2.5) 1.4 (0.8-2.6) 1.4 (0.9-2.4) 0.7 (0.2-3.2) 0.9 (0.3-3.2)
CEP17 0.02 0.02 0.11 0.05 0.33 0.11
   Normal  1 1 1 1 1 1
   Multiplication 1.7 (1.1-2.7) 1.7 (1.1-2.5) 1.6 (0.9-2.8) 1.6 (1.0-2.7) 1.7 (0.6-5.2) 2.1 (0.8-5.4)
CEP17=chromosome 17 centromere; HER2=human epidermal growth factor receptor 2; TOP2A= topoisomerase II alpha; OS=overall survival; DFS=disease-
free survival; HR=hazard ratio; CI=confidence interval.30   Aeri Kim, et al.
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and criteria for defining TOP2A alterations is necessary to dis-
cuss clinical implications of TOP2A alterations. In addition, 
SISH method needs to be validated for TOP2A testing.
The prognostic and predictive value of TOP2A alterations 
remains controversial. In the current study, TOP2A amplifica-
tion, deletion or combined alterations were not predictive of 
DFS or OS. An earlier in vitro study suggested that the sensitiv-
ity to TOP2A inhibitors is dependent on the expression levels 
of TOP2A protein and that TOP2A gene amplification leads 
to better response to anthracycline [10]. Cardoso et al. [3] mea-
sured TOP2A protein expression and TOP2A gene amplifica-
tion using immunohistochemistry and FISH and found that 
TOP2A expression, but not TOP2A gene amplification, was 
correlated with response to anthracyclines. Knoop et al. [4] 
reported that patients with TOP2A amplification had an in-
creased DFS and OS in the subgroup treated with CEF com-
pared to the subgroup treated with CMF. O’Malley et al. [5] 
reported that TOP2A status was not associated with clinical 
outcomes but that treatment with CEF was significantly supe-
rior to treatment with CMF in patients whose tumors showed 
TOP2A alterations (either amplification or deletion). Mukher-
jee et al. [7] reported that TOP2A protein expression strongly 
Figure 4. Kaplan-Meier curves of overall 
survival and disease-free survival accord-
ing to CEP17 copy number. (A, B) Survival 
curves of patients with tumors exhibiting 
non-amplified HER2. (C, D) Survival curves 
in patients with tumors exhibiting amplified 
HER2 status. (E, F) Survival curves of       
patients with tumors exhibiting normal 
TOP2A. (G, H) Survival curves of patients 
with tumors exhibiting altered TOP2A status.
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correlated with pathological complete response to neoadjuvant 
anthracyclines in locally advanced primary breast cancers. 
Bartlett et al. [12] reported that there was no significant       
interaction between anthracycline benefit and HER2 or TOP2A 
alteration but that CEP17 duplication (average CEP17 signals/
cell >1.86) was a predictive biomarker of anthracycline bene-
fit. One of the most interesting findings to us in their study to 
us was that CEP17 duplication was significantly associated with 
OS and relapse-free survival regardless of chemotherapy regi-
men. We also found that CEP17 multiplication (average CEP17 
signals/cell >2) was associated with poor OS and DFS irrespec-
tive of treatment regimen. CEP17 multiplication unrelated to 
HER2 amplification or TOP2A alteration was an independent 
prognostic factor for poor clinical outcome in multivariate 
analysis, but its prognostic significance disappeared in patients 
with TOP2A alteration or HER2 amplification. We were not 
able to compare OS and DFS between the anthracycline and 
non-anthracycline groups according to HER2 and TOP2A   
status and CEP17 multiplication due to the limited number of 
study subjects who received non-anthracyclines and the imbal-
ance of clinicopathological factors between the two groups. 
Although true chromosome 17 polysomy is a rare event, 
CEP17 multiplication is not uncommon in breast cancers [27, 
28]. To date, an aberrant copy number of CEP17 in FISH anal-
yses has been described as chromosome 17 polysomy or aneu-
somy. Marchiò et al. [13] reported that only one of 18 CEP17 
polysomic cases (increased copy number of CEP17 by FISH) 
was true chromosome 17 polysomy by microarray-based com-
parative genomic hybridization and FISH for HER2 (17q12), 
CEP17, SMS (17p11.2), and RARA (17q21.2). Another 17 poly-
somic cases showed a gain of 17q with involvement of the cen-
tromere, 17q gain sparing the centromeric region, or amplifi-
cation of the centromeric region rather than true chromosome 
17 polysomy. For this reason, we described an increased copy 
number of CEP17 signals in SISH analysis as CEP17 multipli-
cation instead of using the traditional term, chromosome 17 
polysomy. The prognostic value of an aberrant copy number 
of CEP17 (described as chromosome 17 polysomy or aneuso-
my in previous reports) has been reported in a limited number 
of studies. 
Krishnamurti et al. [16] reported that HER2-unamplified 
chromosome 17 polysomy (CEP17 signals/cell ≥3) was asso-
ciated with several adverse prognostic indicators such as a higher 
nuclear grade, mitotic activity, Nottingham score, histological 
grade, tumor stage, and estrogen receptor negativity. However, 
they did not correlate chromosome 17 polysomy with clinical 
outcome due to the small number of cases with HER2-unam-
plified chromosome 17 polysomy. Watters et al. [27] reported 
that aneusomy 17 (CEP17 signals/cell <1.35 or >1.86) was 
associated with high grade, ER negativity, and Nottingham 
prognostic index >5.4, but was not associated with survival 
by univariate analysis. As seen in the studies of TOP2A altera-
tion, the criteria defining chromosome 17 polysomy varied in 
different studies [28]. However, it needs to be standardized for 
the assessment of clinical significance of CEP17 multiplication 
in further studies. 
The current study did not elucidate the exact mechanism 
underlying the association between CEP17 multiplication un-
related to HER2 amplification and TOP2A alteration and poor 
prognosis of breast cancer patients. The adverse clinical out-
come could be secondary to activation of unknown oncogenes 
that reside in the locus of chromosome 17 which is close to the 
CEP17 region and is frequently involved in subchromosomal 
duplication or amplification (represented by CEP17 multipli-
cation on SISH analysis).
In conclusion, CEP17 multiplication was associated with 
worse OS and DFS in patients with invasive breast cancers   
exhibiting either non-amplified HER2 or normal TOP2A status. 
Validation in a larger population is needed to provide confir-
matory evidence for the adoption of CEP17 status as a prom-
Table 5. Effect of tumor characteristics on disease-free and overall sur-
vivals in patients with tumors exhibiting normal TOP2A and HER2 status 
(n=393)
Characteristics
Overall survival Disease-free survival
HR (95% CI)    p-value HR (95% CI) p-value
TS>2 cm  4.6 (2.2-9.5) <0.01 2.6 (1.5-4.6) 0.01
LN metastasis 4.7 (2.3-9.8) <0.01 4.4 (2.3-8.4) <0.01
HG 3 2.1(1.1-3.9) 0.02 1.9 (1.1-3.4) 0.03
CEP17  
  multiplication
2.2 (1.2-4.0) 0.01 2.1 (1.2-3.6) 0.01
ER positivity 0.84 (0.5-1.6) 0.59 1.2 (0.6-2.2) 0.60
PR positivity 0.68 (0.4-1.2) 0.18 0.7 (0.4-1.2) 0.20
TOP2A=topoisomerase II alpha; HER2=human epidermal growth factor re-
ceptor 2; HR=hazard ratio; CI=confidence interval; TS=tumor size; LN= 
lymph node; HG=histological grade; CEP17=chromosome 17 centromere; 
ER=estrogen receptor; PR=progesterone receptor.
Table 6. Multivariate analysis of factors associated with disease-free 
and overall survivals in patients with tumors exhibiting normal TOP2A 
and HER2 status
Characteristics
Overall survival Disease-free survival
HR (95% CI)    p-value HR (95% CI) p-value
TS>2 cm  3.3 (1.5-7.4) <0.01 1.7 (0.9-3.2) 0.10
LN metastasis 3.1 (1.4-6.5) <0.01 3.2 (1.6-6.1) <0.01
HG 3 1.3 (0.7-2.6) 0.38 1.5 (0.8-2.7) 0.20
CEP17  
  multiplication
2.2 (1.1-4.2) 0.02 2.3 (1.2-4.1) 0.01
TOP2A=topoisomerase II alpha; HER2=human epidermal growth factor re-
ceptor 2; HR=hazard ratio; CI=confidence interval; TS=tumor size; LN= 
lymph node; HG=histological grade; CEP17=chromosome 17 centromere.32   Aeri Kim, et al.
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ising prognostic biomarker in routine clinical practice of breast 
cancers. Further studies should be performed to examine mo-
lecular mechanism underlying the association between CEP17 
multiplication and adverse clinical outcome. 
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